



**March 10, 2023**

**To**  
**Corporate Relations Department**  
**BSE Limited**

**Sub:** Vayam Research Solutions Limited, Associate Company (indirect) of Vanta Bioscience Limited has cleared USFDA audit with Zero 483s

**Ref:** Disclosure under Reg 30 of SEBI (LODR), Regulation, 2015

We are happy to inform that Vayam Research Solutions Limited ("**Vayam**"), Associate of Vanta Bioscience Limited (Associate of WOS of Vanta Bioscience Limited) has cleared USFDA audit with Zero 483s for its facility at Gandhi Nagar, Gujarat carried out by the office of study integrity and surveillance,

The said approval will help Vayam to enhance customer service portfolio in various segments like pharmaceutical as well as nutraceutical clinical trial and BA/BE studies around the world.

In terms of SEBI CIR/CFD/CMF/4/2015 dated September 09, 2015, we hereby submit the following information with regards to license received by the Associate:

Name of the regulatory or licensing authority	US Food and Drug Administration (USFDA)
Brief Details of approval/license obtained	It is a product specific approval and applicable to all the countries following US Food and Drug Administration (USFDA) regulations.
Impact/relevance of such approval/license to the listed entity	The said approval will help Vayam to enhance customer service portfolio in various segments like pharmaceutical as well as nutraceutical clinical trial and BA/BE studies around the world.
Withdrawal/cancellation or suspension of licence/approval by the regulatory or licensing authority, with reasons for such	NA



## Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,  
Rasoolpura, Secunderabad - 500 003, INDIA.  
Tel : +91 40 6657 5454, 2790 3226  
Fax : +91 40 2790 8708  
Website : www.vantabio.com  
Email : info@vantabio.com  
CIN No. : L74999TG2016PLC109280

action, estimated impact (monetary or otherwise) on the listed entity and penalty, if any	
Period for which such approval/license is/was valid	NA
Subsequently, the listed entity shall inform the stock exchange(s), the actual impact (monetary or otherwise) along with corrective actions taken by the listed entity pursuant to the withdrawal, cancellation or suspension of the key license/ approval	NA

Accordingly, the Trading Window for all designated persons as under Insider Trading Policy of the Company is closed from March 11, 2023 till closing hours of March 13, 2023.

This is for your information and dissemination to general public.

**for VANTA BIOSCIENCE LIMITED**  
**(Scrip Code: 540729 | Scrip ID:VANTABIO)**

**VENKATA SATHYA MURALI DOKKA**  
**CHIEF FINANCIAL OFFICER**